Janux Therapeutics (JANX) Enterprise Value (2021 - 2026)

Janux Therapeutics (JANX) has reported Enterprise Value for 7 consecutive years, with -$956.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 5.7% year-over-year to -$956.4 million; the TTM figure through Mar 2026 stood at -$956.4 million (up 5.7% YoY), while the FY2025 annual figure was -$966.6 million, up 5.72% from the prior year.
• Enterprise Value improved to -$956.4 million in Q1 2026 per JANX's latest filing, from -$966.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$303.3 million in Q2 2023 and bottomed at -$1.0 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$623.4 million across 5 years, with a median of -$646.3 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value rose 14.4% — and 2024, when it plunged 197.99%.
• Janux Therapeutics' Enterprise Value stood at -$327.0 million in 2022, then dropped by 5.2% to -$344.0 million in 2023, then slumped by 197.99% to -$1.0 billion in 2024, then rose by 5.72% to -$966.6 million in 2025, then rose by 1.05% to -$956.4 million in 2026.
• Business Quant data shows JANX's Enterprise Value at -$956.4 million in Q1 2026, -$966.6 million in Q4 2025, and -$989.0 million in Q3 2025.